HC Wainwright & Co. Maintains Buy on MiNK Therapeutics, Lowers Price Target to $9

Benzinga · 03/21 15:27
HC Wainwright & Co. analyst Emily Bodnar maintains MiNK Therapeutics (NASDAQ:INKT) with a Buy and lowers the price target from $10 to $9.